1. Dean, L.E., Jones, G.T., MacDonald, A.G., et al., Global prevalence of ankylosing spondylitis, Rheumatology, 2014, vol. 53, no. 4, p. 650.
2. Erdes, Sh.F., Interleukin 17a—a new target for anticytokine therapy in ankylosing spondylitis, Nauchno-Prakt.
Revmatol., 2016, vol. 54, suppl. 1, p. 60.
3. Zarco, P., Gonzalez, C., Rodriguez de la Serna, A., et al., Extra-articular disease in patients with spondyloarthritis: baseline characteristics of the spondyloarthritis cohort of the AQUILES study, Reumatol. Clin., 2015, vol. 11, no. 2, p. 83.
4. Kunder, E.V., Treatment of patients with ankylosing spondylitis, Mezhdunar. Obz.: Klini. Prakt. Zdorov’e, 2013, no. 4, p. 55.
5. Yakovlev, M.Yu., Sistemnaya endotoksinemiya: gomeostaz i obshchaya patologiya (Systemic Endotoxinemia: Homeostasis and General Pathology), Moscow: Nauka, 2021.